A paper using ChemAxon's property calculation tools has been published in Nature Reviews Drug Discovery.
パトコア
The pharmaceutical industry is constantly under immense pressure to address the high attrition rates in drug development. Efforts to reduce the number of failures related to efficacy and safety through the analysis of potential correlations with the physicochemical properties of low molecular weight candidate compounds have not yielded clear conclusions due to limitations in data volume at various companies. This paper retrospectively analyzes drug candidates from AstraZeneca, Eli Lilly, GlaxoSmithKline, and Pfizer, discussing their efficacy. The aforementioned companies use ChemAxon's property calculation tools to perform physicochemical property calculations.
Related Links
This paper analyzes drug candidates from various pharmaceutical companies using ChemAxon's property calculation tool to calculate physicochemical properties and discusses their efficacy.